Top Markets
#1 ADO Protocol ADO Protocol +193.34%
#2 Islamic Coin Islamic Coin +155.37%
#3 GoPlus Security GoPlus Security +44.27%
#4 GAIB AID GAIB AID +24.67%
#5 SkyAI SkyAI +14.39%
#6 Verus Coin Verus Coin +13.64%
#7 o1.exchange o1.exchange +12.48%
#8 Tutorial Tutorial +12.27%
#9 Casper Network Casper Network +12.23%
#10 Pons Pons +12.22%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
Vascular Biogenics Ltd. Vascular Biogenics Ltd.

Vascular Biogenics Ltd.

VBLT
Rank in Stocks #33544
Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical... Vascular Biogenics Ltd. (VBLT) operates as a clinical-stage biopharmaceutical company, dedicated to developing therapeutic solutions for cancer and immune-inflammatory diseases. The company's activities are concentrated in Israel and the United States. Its pipeline is anchored by two core technological platforms: First, a gene-based vascular targeting system that focuses on newly formed blood vessels; and second, an antibody-based monocyte targeting technology that aims to specifically inhibit monocyte migration, particularly for immune-inflammatory applications. VBLT's flagship product candidate, VB-111, a gene-based biologic, is undergoing several clinical trials. It has reached Phase III for the treatment of recurrent, platinum-resistant ovarian cancer. Additionally, it is in Phase II trials for recurrent glioblastoma and colorectal cancer. Moreover, VB-111 has completed Phase II clinical trials for thyroid cancer. The company is also developing VB-601 for a variety of inflammatory indications and VB-611 for different types of solid tumors. Initially incorporated as Medicard Ltd. in 2000, the company rebranded as Vascular Biogenics Ltd. in January 2003. Its main offices are situated in Modi'in, Israel.
Share Price
$0.155
Last synced: 2023-10-16
Market Cap
$7.44M
Change (1 day)
-9.36%
Change (1 year)
0.00%
Country
IL
Trade Vascular Biogenics Ltd. (VBLT)

Category

Healthcare
Revenue for Vascular Biogenics Ltd. (VBLT)
Revenue in Aug 2026 TTM: 0
According to Vascular Biogenics Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Vascular Biogenics Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE